Summary
The effects of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in 37 patients with ischemic heart disease were examined in a randomized, multicenter study. Nicorandil (n=20, 10–40 mg/day, b.i.d.) and diltiazem (n=17, 60–240 mg/day, b.i.d.) were administered for 12 weeks. Both nicorandil and diltiazem administration showed an effective antianginal effect. Diltiazem administration showed a significant hypotensive action. There were no significant changes in serum lipids, apolipoproteins, and lipoproteins for both nicorandil and diltiazem. There were no significant changes in body weight, uric acid, and fasting blood sugar levels during the test period for both drugs. These data show that nicorandil, like diltiazem, does not have any adverse effects on lipid metabolism and that it is a favorable drug to use as an agent for treating arteriosclerotic heart disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 115 mmHg. JAMA 1970; 213:1143–1152.
Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens 1985;3: 297–306.
Arakawa K, Sasaki J. Effects of cardiovascular drugs on serum lipoproteins. In: Zusmann RM, ed. Cardioprotection by converting enzyme inhibition. Princeton: Excerpta Medica, 1988:43–50.
Sakai K, Nakano H, Nagano H, Uchida Y. Nicorandil. In: Scriabine A, ed. New drugs annual: Cardiovascular drugs. New York: Raven Press, 1983:227–239.
Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63:18J-24J.
Levenson J, Bouthier J, Chau NP, et al. Effects of nicorandil on arterial and venous vessels of the forearm in systemic hypertension. Am J Cardiol 1989;40J–43J.
Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;70:470–475.
Eggstein M, Kreutz FH. Eine neue bestimmung der neutralfette in blutseum und gewebe. Klin Wochenscr 1966;44: 262–267.
Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 1978;19: 65–76.
Havel RJ, Edger HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345–1353.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without using the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
Goto Y, Akanuma Y, Harano Y, et al. Determination by the SRID method of normal values of serum apolipoproteins (A-I, A-II, B, C-II, C-III, and E) in normolipemic healthy Japanese subjects. J Clin Biochem Nutr 1986;1:73–88.
Vessby B, Abelin J, Finnson M, et al. Effects of nifedipine treatment on carbohydrate and lipoprotein metabolism. Curr Ther Res 1983;33:1075–1080.
Schulte KL, Meyer-Sabllek WA, Haertenberger A, et al. Antihypertensive and metabolic effects of diltiazem and nifedipine. Hypertension 1986;8:859–865.
Sasaki J, Arakawa K. Effect of nifedipine on serum lipids, lipoproteins, and apolipoproteins in patients with essential hypertension. Curr Ther Res 1987;41:845–851.
Pool PE, Seagren SC, Sable AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: Randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985;56:86H-91H.
Walldius G. Effect of verapamil on serum lipoprotein in patients with angina pectoris. Acta Med Scand 1982;681 (Suppl):43–48.
Lewis GRJ. Long-term results with verapamil in essential hypertension and its influence on serum lipids. Am J Cardiol 1986;57:35D-38D.
Ishida N, Matsuo R, Migita T, et al. Effects of nicardipine HCI on serum lipids and blood pressure. J Jpn Atheroscler Soc 1984;12:833–838.
Johnson BF, Romero L, Marwaha R. Hemodynamics and metabolic effects of the calcium channel blocking agent nitrendipine. Clin Pharmacol Ther 1986;39:389–394.
Tamai T, Maeda H, Takahashi S, et al. Effects of verapamil, diltiazem and nicorandil on low-density lipoprotein metabolism in eulfured human skin fibroblasts and rats hepatoma cells. J Jpn Atheroscler Soc 1988;16:423–428 (in Japanese with English abstract).
Author information
Authors and Affiliations
Additional information
This paper was presented, in part, at the 3rd Cardiovascular Pharmacotherapy International Symposium, October 15–19, 1989, Kyoto, Japan.
Rights and permissions
About this article
Cite this article
Sasaki, J., Saeki, Y., Kawasaki, K. et al. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease. Cardiovasc Drug Ther 6, 471–474 (1992). https://doi.org/10.1007/BF00055603
Issue Date:
DOI: https://doi.org/10.1007/BF00055603